Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

0(0%)

Results Posted

200%(4 trials)

Terminated

3(60%)

Phase Distribution

Ph phase_2

60%

Ph early_phase_1

20%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(3)

Detailed Status

Terminated3

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (20.0%)

Phase 11 (20.0%)

Phase 23 (60.0%)

Trials by Status

completed240%

terminated360%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_2

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

NCT02142608

Clinical Trials (5)

Showing 5 of 5 trials

NCT03493464Phase 2

BR55 in Characterization of Ovarian Lesions

Terminated

NCT04248153Phase 2

Optimal Timing of BR55 CEUS of the Ovaries

Terminated

NCT03486327Phase 2

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

Terminated

NCT01253213Early Phase 1

BR55 in Prostate Cancer: an Exploratory Clinical Trial

Completed

NCT02142608Phase 1

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5